Jun 21, 2024, 07:58
Cancer Therapy Advisor – Results, from the STARGLO trial presented at EHA2024 by Dr Jeremy Abramson
Cancer Therapy Advisor shared a post on X:
“Glofitamab plus GemOx improved outcomes over rituximab plus GemOx in transplant-ineligible patients with relapsed/refractory DLBCL. These results, from the STARGLO trial, were presented at EHA2024 by Dr Jeremy Abramson from Mass General Cancer Center.”